Ventfort

Ventfort is a peptide complex bioregulator, classified as a Cytomax for the vascular wall in the Khavinson system. It is manufactured by extraction from aortic tissue of young calves using a patented process developed at the St. Petersburg Institute of Bioregulation and Gerontology. The active fraction, called peptide complex A-3, contains short peptides with molecular weights ranging up to approximately 10 kDa.

The Khavinson bioregulator program operates on two parallel pillars. Cytomaxes are organ-specific peptide extracts from young animal tissue. They contain multiple short peptides and are marketed under product names tied to their source tissue: Ventfort (vessels), Cerluten (brain), Svetinorm (liver), Sigumir (cartilage and bone), Chelohart (heart), Suprefort (pancreas), Chitomur (bladder), among others. Cytogens are short synthetic peptides, typically two to four amino acids, designed to reproduce a single active fragment isolated from the corresponding Cytomax. For the vascular system, the Cytomax is Ventfort and the Cytogen is Vesugen (Lys-Glu-Asp, KED).

The proposed mechanism is direct DNA interaction. The Khavinson group has published a series of papers describing how short peptides translocate into cell nuclei, bind double-stranded DNA in promoter regions, and modulate transcription of tissue-specific genes. The 2020 review by Khavinson and coauthors in Biomedicines summarizes the binding model. Independent confirmation of this mechanism by Western groups is sparse, and the model has not been directly tested for Ventfort's specific peptide composition.

The compound is positioned within a broader cardiovascular bioregulator family that includes Chelohart (heart Cytomax) and its Cytogen counterpart Cardiogen, plus Vesugen for the vascular wall (Cytogen). The Khavinson group reports clinical use data spanning several decades from Russian and former-Soviet medical institutions. This data is presented in Russian-language publications, conference proceedings, and books rather than in English-language peer-reviewed trials indexed in major Western databases.

The Human Evidence

The compound-specific clinical evidence base sits inside a single institutional network. Reports describe:

• Improvement in vascular tone and elasticity parameters in elderly patients
• Microcirculation improvements measured by capillaroscopy or laser Doppler
• Modulation of blood pressure variability
• Use as part of comprehensive bioregulator protocols in geriatric medicine

Most of these reports are observational. The Korkushko series on Khavinson bioregulators in elderly populations is the most-cited body of work and describes long-term outcomes in cohorts followed at the Institute of Gerontology in Kiev. The methodology is non-randomized and is not blinded against placebo.

The compound has not been tested in:

• A registered ClinicalTrials.gov study
• A peer-reviewed English-language randomized controlled trial
• A pharmacokinetic study with measured plasma peptide levels
• An independent multi-center safety and efficacy program

PubMed search for "Ventfort" returns no clinical trials as of May 2026. Search for "peptide complex A-3 vascular" returns only Khavinson-affiliated publications.

Regulatory and Legal Status

FDA. No approval. Not listed on bulk drug substances list. Importation permitted only as a research chemical labeled "not for human consumption."

EMA. No approval.

Russia. Registered as a biologically active dietary supplement under the Khavinson distribution network. Sold in retail capsule and sublingual liquid formats.

WADA. Not on the 2026 Prohibited List.

The animal-tissue origin of Ventfort places it in a separate regulatory category from synthetic peptides. Bovine-derived products face additional scrutiny under various national regulations governing prion risk and infectious-agent screening. The Khavinson manufacturing process documentation describes sourcing standards, but independent third-party audit information is not publicly available.

The proposed mechanism follows the broader Khavinson bioregulation model with vessel-specific tissue targeting.

Cellular entry. Short peptides from the Ventfort complex are hypothesized to enter cells through peptide transporters (PEPT1, PEPT2), reach the nucleus, and bind DNA in vessel-related gene promoters. Endothelial cells, vascular smooth muscle cells, and the connective-tissue elements of the vascular wall are the proposed targets.

Gene-expression effects. Khavinson group publications describe normalization of protein synthesis patterns in vascular wall cells, modulation of expression of genes involved in vasomotor function, and shifts in markers of endothelial activation. The specific genes affected have not been mapped by independent transcriptomic studies for Ventfort specifically. Similar work has been done for Epitalon (pineal Cytogen) using human cell lines and is referenced in support of the general bioregulator model.

Tissue-specificity claim. The Khavinson group asserts that Cytomax extracts retain tissue selectivity through preferential gene-promoter binding, even though they contain a heterogeneous mix of peptides up to 10 kDa. The molecular basis for this selectivity is not fully established at the single-molecule level. Each Cytomax is defined functionally by its tissue of origin and clinical effects rather than by a complete chemical characterization of all active components.

Pharmacokinetics. Bovine-origin peptide complexes face the same challenge as any orally administered peptide: gut hydrolysis to free amino acids and short fragments. The Khavinson group has proposed that the relevant pharmacological event occurs at the gut-mucosa interface and is signaled systemically through neural and humoral pathways rather than requiring intact peptide delivery to the target tissue. Direct measurement of plasma peptide levels after Ventfort administration has not been published in peer-reviewed form.

Human pharmacokinetic data is not published in any English-language peer-reviewed journal.

Reported effects from Russian-institution clinical observation studies include:

• Improvement in vascular tone and arterial wall elasticity
• Microcirculation improvements
• Stabilization of blood pressure variability
• Improvement in cold-extremity symptoms in elderly patients
• Possible adjunct effect in post-stroke recovery protocols
• Reduced ischemic-event incidence in observational cohorts

Research-chemical user reports outside Russia are less common for Cytomaxes than for Cytogens, since the oral-capsule format dominates retail distribution. User reports tend to describe subtle, gradual effects over multiple courses rather than acute changes.

None of these effects has been quantified in a placebo-controlled trial. The institutional reports are not blinded and are produced by groups connected to the compound's developer.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Ventfort.

The Russian retail product (Ventfort capsules) is dosed as 1 to 2 capsules once or twice daily during meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 10 mg of active vascular peptide complex.

Sublingual liquid formats provide 10 mg of active peptide per 1 mL dose, taken once daily under the tongue for absorption through the oral mucosa. The rationale for sublingual delivery is bypass of first-pass intestinal hydrolysis.

The course-and-cycle dosing pattern is a standard feature of Khavinson protocols. The theoretical rationale is that bioregulator effects persist between cycles through induced changes in gene expression, so continuous dosing is not required. Independent confirmation of cycle-spacing optimization is absent. Khavinson group publications report durable effects for several months after a single 30-day course.

Research-chemical subcutaneous Ventfort is uncommon. Cytomax complexes are typically formulated for oral or sublingual delivery rather than injection, because injection of a heterogeneous bovine-derived peptide mixture carries higher infection and immunogenicity concerns than injection of a single synthetic peptide.

The Khavinson bioregulator class has a notably benign published adverse-event profile. The Russian manufacturer documentation lists individual intolerance to components, pregnancy, lactation, and age below 14 years as the only formal contraindications. No serious adverse events have been reported in the published Russian-language literature.

The animal-origin nature of the compound creates a distinct safety profile compared with synthetic Cytogens. Theoretical concerns specific to Ventfort include:

• Contamination risk from bovine source tissue (manufacturing controls described but not independently audited)
• Theoretical prion-related concerns from bovine-derived products
• Potential immunogenicity from foreign-protein exposure
• Endotoxin risk in injectable forms

The Russian manufacturer documentation describes sourcing standards and quality controls, but third-party verification of these standards by Western regulatory bodies has not been performed at the level required for FDA or EMA approval of a biologic product.

Long-term human safety data with controlled endpoints does not exist. The Khavinson group has reported cumulative safety experience from decades of Russian clinical use, which is informative but is not equivalent to a structured long-term safety database with pre-specified organ system monitoring.

Drug-drug interaction data is absent. Ventfort use alongside antihypertensives, anticoagulants, or statins has not been studied in controlled human trials.

Within the Khavinson system, Ventfort is typically preceded by its Cytogen counterpart Vesugen (Lys-Glu-Asp, KED) in a sequential protocol. Vesugen is positioned as the initial-phase synthetic peptide that primes vascular tissue, followed by Ventfort as the broader multi-peptide complex for sustained support.

For comprehensive cardiovascular protocols, Ventfort is combined with Cardiogen (heart Cytogen) and sometimes thymus-targeting bioregulators such as Thymogen (Cytogen) or Vladonix (Cytomax). The combined approach is the Khavinson model of multi-organ bioregulation.

For geroprotective stacks, Ventfort is one component of the so-called "first-class stack" of major-system bioregulators, alongside Cerluten (brain), Svetinorm (liver), Sigumir (cartilage and bone), and Vladonix (thymus). No combined-stack human trial has been published.

The closest pharmaceutical comparators by claimed effect are ACE inhibitors, statins, and various endothelial-function-improving agents. These have decades of randomized controlled trial data demonstrating reduction in cardiovascular events. Ventfort has no such evidence base. Treating one as a substitute for the other is not supported by the available data.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.